OPKO seeks FDA approval to begin Phase IIa trial of Factor VIIa-CTP to treat hemophilia
Factor VIIa-CTP is a new, long-acting recombinant Factor VIIa using the company’s proprietary technology to extend its circulatory half-life without the use of polymers, encapsulation techniques or nanoparticles.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.